MedTrace Logo

Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

NCT00749021 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-10-05

No results posted yet for this study

Summary

This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.

Conditions

  • Retinal Pigment Epithelial Detachment

Interventions

DRUG

Ranibizumab

0.5 mg of intravitreal ranibizumab monthly for 12 months

DRUG

Ranibizumab

0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing

DRUG

Ranibizumab

2.0mg of intravitreal ranibizumab monthly for 12 months

DRUG

Ranibizumab

2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing

Sponsors & Collaborators

  • Clement K. Chan

    lead OTHER

Principal Investigators

  • Clement K Chan, M.D. · Southern California Desert Retina Consultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00749021 on ClinicalTrials.gov